<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377152</url>
  </required_header>
  <id_info>
    <org_study_id>EA-HOPE20200129</org_study_id>
    <secondary_id>20-30046</secondary_id>
    <nct_id>NCT04377152</nct_id>
  </id_info>
  <brief_title>Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer</brief_title>
  <official_title>Expanded Access: 68Gallium-PSMA-11 for PET Imaging of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      This expanded access protocol provides eligible participants with investigational&#xD;
      68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent&#xD;
      treatment strategy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Prostate Cancer</condition>
  <condition>Prostate</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Gallium-PSMA-11</intervention_name>
    <description>PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).</description>
    <other_name>PSMA-HBED-CC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity</description>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Biochemical recurrent and pre-prostatectomy staging participants will be eligible and must&#xD;
        meet the following criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Histopathologically confirmed or biopsy proven prostate adenocarcinoma.&#xD;
&#xD;
          3. Concern for metastatic disease in one of the following settings:&#xD;
&#xD;
               1. Initial staging with intermediate to high risk prostate cancer.&#xD;
&#xD;
               2. Biochemical recurrence after initial therapy.&#xD;
&#xD;
          4. Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by&#xD;
        the Investigator to be unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

